KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Thermo Fisher Scientific (TMO) Change in Account Payables (2016 - 2020)

Thermo Fisher Scientific (TMO) has disclosed Change in Account Payables for 12 consecutive years, with $279.0 million as the latest value for Q4 2020.

  • For the quarter ending Q4 2020, Change in Account Payables rose 42.35% year-over-year to $279.0 million, compared with a TTM value of $59.0 million through Dec 2020, down 77.82%, and an annual FY2025 reading of $421.0 million, up 98.58% over the prior year.
  • Change in Account Payables was $279.0 million for Q4 2020 at Thermo Fisher Scientific, up from $277.0 million in the prior quarter.
  • Across five years, Change in Account Payables topped out at $279.0 million in Q4 2020 and bottomed at -$256.0 million in Q2 2020.
  • Average Change in Account Payables over 5 years is $42.8 million, with a median of $15.6 million recorded in 2016.
  • Peak annual rise in Change in Account Payables hit 2812.87% in 2017, while the deepest fall reached 1374.51% in 2017.
  • Year by year, Change in Account Payables stood at -$10.1 million in 2016, then surged by 2812.87% to $274.0 million in 2017, then decreased by 10.22% to $246.0 million in 2018, then decreased by 20.33% to $196.0 million in 2019, then soared by 42.35% to $279.0 million in 2020.
  • Business Quant data shows Change in Account Payables for TMO at $279.0 million in Q4 2020, $277.0 million in Q3 2020, and -$256.0 million in Q2 2020.